Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ)
CNY 21.55
(-0.23%)
CNY 21.55
(-0.23%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 258.46 Million CNY | 51.36% |
| 2022 | 170.76 Million CNY | 26.16% |
| 2021 | 135.35 Million CNY | 76.69% |
| 2020 | 76.6 Million CNY | 0.47% |
| 2019 | 76.25 Million CNY | 22.06% |
| 2018 | 62.47 Million CNY | 32.77% |
| 2017 | 47.05 Million CNY | 13.88% |
| 2016 | 41.31 Million CNY | 44.6% |
| 2015 | 28.57 Million CNY | 60.95% |
| 2014 | 17.75 Million CNY | 47.51% |
| 2013 | 12.03 Million CNY | 23.65% |
| 2012 | 9.73 Million CNY | -50.29% |
| 2011 | 19.57 Million CNY | -2.49% |
| 2010 | 20.07 Million CNY | 111.5% |
| 2009 | 9.49 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 231.7 Million CNY | -29.09% |
| 2024 Q2 | 326.76 Million CNY | 35.49% |
| 2024 Q1 | 241.17 Million CNY | -6.69% |
| 2023 FY | 258.46 Million CNY | 51.36% |
| 2023 Q3 | 242.77 Million CNY | -16.53% |
| 2023 Q1 | 163.68 Million CNY | -4.14% |
| 2023 Q4 | 258.46 Million CNY | 6.46% |
| 2023 Q2 | 290.86 Million CNY | 77.7% |
| 2022 Q1 | 86.69 Million CNY | -35.95% |
| 2022 FY | 170.76 Million CNY | 26.16% |
| 2022 Q4 | 170.76 Million CNY | 25.25% |
| 2022 Q3 | 136.33 Million CNY | 22.07% |
| 2022 Q2 | 111.68 Million CNY | 28.83% |
| 2021 Q3 | 123.66 Million CNY | 42.92% |
| 2021 Q4 | 135.35 Million CNY | 9.45% |
| 2021 Q2 | 86.52 Million CNY | -8.26% |
| 2021 Q1 | 94.31 Million CNY | 23.12% |
| 2021 FY | 135.35 Million CNY | 76.69% |
| 2020 Q2 | 63.53 Million CNY | 6.39% |
| 2020 Q1 | 59.71 Million CNY | -21.69% |
| 2020 FY | 76.6 Million CNY | 0.47% |
| 2020 Q3 | 81.06 Million CNY | 27.61% |
| 2020 Q4 | 76.6 Million CNY | -5.5% |
| 2019 FY | 76.25 Million CNY | 22.06% |
| 2019 Q4 | 76.25 Million CNY | 5.68% |
| 2019 Q3 | 72.15 Million CNY | 42.83% |
| 2019 Q2 | 50.51 Million CNY | -0.66% |
| 2019 Q1 | 50.85 Million CNY | -18.6% |
| 2018 Q3 | 49.25 Million CNY | -2.44% |
| 2018 Q2 | 50.48 Million CNY | 0.81% |
| 2018 Q1 | 50.07 Million CNY | 6.42% |
| 2018 FY | 62.47 Million CNY | 32.77% |
| 2018 Q4 | 62.47 Million CNY | 26.84% |
| 2017 Q2 | 34.67 Million CNY | -1.09% |
| 2017 Q4 | 47.05 Million CNY | 11.33% |
| 2017 FY | 47.05 Million CNY | 13.88% |
| 2017 Q3 | 42.26 Million CNY | 21.9% |
| 2017 Q1 | 35.05 Million CNY | -15.16% |
| 2016 FY | 41.31 Million CNY | 44.6% |
| 2016 Q2 | 27.49 Million CNY | -2.56% |
| 2016 Q1 | 28.21 Million CNY | -1.26% |
| 2016 Q4 | 41.31 Million CNY | 20.95% |
| 2016 Q3 | 34.16 Million CNY | 24.25% |
| 2015 Q3 | 21.39 Million CNY | 16.69% |
| 2015 Q2 | 18.33 Million CNY | 14.03% |
| 2015 FY | 28.57 Million CNY | 60.95% |
| 2015 Q1 | 16.08 Million CNY | -9.41% |
| 2015 Q4 | 28.57 Million CNY | 33.52% |
| 2014 Q2 | 13.62 Million CNY | -25.18% |
| 2014 Q1 | 18.2 Million CNY | 51.29% |
| 2014 Q4 | 17.75 Million CNY | -7.7% |
| 2014 FY | 17.75 Million CNY | 47.51% |
| 2014 Q3 | 19.23 Million CNY | 41.17% |
| 2013 Q4 | 12.03 Million CNY | -11.06% |
| 2013 Q1 | - CNY | -100.0% |
| 2013 Q2 | 10.62 Million CNY | 0.0% |
| 2013 FY | 12.03 Million CNY | 23.65% |
| 2013 Q3 | 13.53 Million CNY | 27.33% |
| 2012 Q4 | 9.73 Million CNY | 0.0% |
| 2012 FY | 9.73 Million CNY | -50.29% |
| 2011 FY | 19.57 Million CNY | -2.49% |
| 2010 FY | 20.07 Million CNY | 111.5% |
| 2009 FY | 9.49 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 9.12 Billion CNY | 97.168% |
| Zhejiang Zhenyuan Share Co., Ltd. | 974.86 Million CNY | 73.488% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | 1.21 Billion CNY | 78.71% |
| Hubei Guangji Pharmaceutical Co., Ltd. | 1.63 Billion CNY | 84.212% |
| Yifan Pharmaceutical Co., Ltd. | 3.14 Billion CNY | 91.782% |
| Guangdong Jiaying Pharmaceutical Co., Ltd | 84.57 Million CNY | -205.586% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 13.22 Billion CNY | 98.045% |
| Chongqing Lummy Pharmaceutical Co., Ltd. | 762.32 Million CNY | 66.096% |
| Boai NKY Medical Holdings Ltd. | 499.66 Million CNY | 48.273% |